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Short Title: Triage strategies for High-risk HPV positive women  
Key words: HPV, triage, screening, roadmap 
 
Novelty and impact: Second line or “triage” tests that can risk–stratify HR-HPV positive women are 
needed urgently for cervical screening.  Through the vehicle of the “EUROGIN roadmap”, we present 
the current state of the art in triage options, in addition to describing emerging technologies and 
challenges to implementation. Given that several countries have, or are soon to implement, HPV 
based screening nationally, such a review is timely. 
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Abstract  
Cervical cancer screening will rely, increasingly, on HPV testing as a primary screen. The requirement 
for triage tests which can delineate clinically significant infection is thus prescient. In this EUROGIN 
2017 roadmap, justification behind the most evidenced triages is outlined, as are challenges for 
implementation.  
Cytology is the triage with the most follow-up data; the existence of an HR-HPV positive, cytology 
negative group presents a challenge and re-testing intervals for this group (and choice of re-test) 
require careful consideration.  Furthermore, cytology relies on subjective skills and while adjunctive 
dual-staining with p16/Ki67 can mitigate inter-operator/site disparities, clinician-taken samples are 
required. Comparatively, genotyping and methylation markers are objective and are applicable to self-
taken samples, offering logistical advantages including in low and middle income settings. However, 
genotyping may have diminishing returns in immunised populations and type(s) included must 
balance absolute risk for disease to avoid low specificity. While viral and cellular methylation markers 
show promise, more prospective data are needed in addition to refinements in automation.   
Looking forward, systems that detect multiple targets concurrently such as next generation 
sequencing platforms will inform the development of triage tools. Multi-step triage strategies may be 
be beneficial provided they do not create complex, unmanageable pathways. Inevitably, the balance 
of risk to cost(s) will be key in decision making, although defining an acceptable risk will likely differ 
between settings.  Finally, given the significant changes to cervical screening and the variety of triage 
strategies, appropriate education of both health care providers and the public is essential.  
 
 
 
 
 
Introduction 
HPV testing for cervical cancer screening is now a reality with several countries, either adopting this 
modality at the programme level or introducing it through the execution of regional pilot studies (1). 
Support for this approach to screening is also endorsed by various professional societies and 
organisations which have global influence and reach (2-5).  While there is a wide and growing 
consensus that HPV molecular testing is the most accurate and cost-effective method of primary 
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screening, there is a comparative lack of consensus regarding the optimal means of risk stratification 
or “triage” of primary HPV infections. This is evidenced by the heterogeneity of triage algorithms 
either proposed or applied across various settings [(6) and Table 1].  Given that most HPV infections 
follow a benign course, effective triage is crucial to ensure the screening participant is not subject to 
the burden of unnecessary follow-up and that resources are used efficiently. This point is further 
emphasised by the fact that compared to cytology based primary screening, HPV testing will generate 
significantly more screen “positives” in the initial round of screening (7). 
As a growing number of countries prepare for HPV primary screening, the triage issue becomes 
particularly timely. This urgency was reflected at the EUROGIN 2016 meeting, where several of the 
scientific papers focussed on the application of triage strategies. Consequently, a group of experts 
were tasked with using the vehicle of the now established “Eurogin roadmap” (the eleventh Roadmap 
release since 2007) to outline evidence, benefits and challenges surrounding current triage strategies 
and to summarise some of the key technical developments in both sampling and diagnostics that may 
bear influence. 
 
Cytology 
Arguably, the strategy with the longest available follow up data is cytology. Cytological triage of HPV-
positive women has been evaluated within three European randomised controlled trials, initially 
designed to compare HPV testing (alone or with cytology concurrently) to cytology screening over two 
screening rounds (8-10). 
Notwithstanding minor protocol differences across these trials, women with abnormal cytology were 
referred to colposcopy while the remainder were recalled to repeat an HPV test; alone or with 
cytology, after 6-18 months and referred to colposcopy in the case of persistent positivity (type 
specific in one study).  All studies showed a significantly reduced occurrence of CIN3+ in the HPV arm 
at round 2.  In addition, a pooled analysis of 4 studies with data on two screening rounds, including 
the three described, (and one without triage), found significantly less cancer in the HPV arm with no 
evidence of heterogeneity between studies. Conversely, the biopsy rate was similar between arms in 
the studies with cytological triage but higher in the trial without it (11). Thus, cytological triage with 
HPV repeat-testing in cytology-negative women can be considered validated. In the aforementioned 
trials, cytology interpretation was blind to HPV result. In a Finnish trial (performed over one screening 
round) cytology was performed on HPV-positive women, with knowledge of HPV status. Interestingly, 
the detection of CIN was higher in the HPV arm even when considering only referrals due to reflex 
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abnormal cytology (12). This suggests that knowledge of HPV positivity may affect the performance of 
cytology.  This observation is consistent with a sub-study of the NTCC trial where HPV positive Paps 
were dispatched for external cytology review to a laboratory blinded to information other than HPV 
status.  The cross-sectional relative sensitivity for CIN2+ of HPV informed vs blind cytology was 1.58 
(95% CI = 1.22 to 2.01) (13). An important consideration, however, is that as cytology relies on 
subjective morphological assessment, between-site variation in interpretation and performance can 
be expected (14).  In 2012, in ten Italian routine, local programmes based on HPV testing, the 
proportion of HPV positive women judged with  ≥ASC-US varied from 20.0% to 56.9%. (14). This said, 
it should be noted that, as a consequence of the screening protocol applied (HPV+/cytologically 
normal women at baseline were referred to colposcopy if still HPV+ at 12 months), this variation had 
a relative small impact on the colposcopy referral rate, at baseline or at 12 months (only a 4.2% 
increase for a 10% increase in immediate referral) (15) However, the total number of colposcopies is 
also dependent on the follow-up guidelines of women with a negative colposcopy.  
 More generally the above data show that when judging the performance of any triage approach, the 
entire process should be taken into account i.e. not just the immediate triage test. Improvements to 
immediate triage tests can be fully exploited only if the interval to re-testing is considered carefully.  
Finally, a practical consideration of cytology-triage is that it requires a highly-skilled workforce and 
significant investment in ongoing quality assurance to perform optimally.  This is possible and has 
precedent in high-income countries with the relevant infrastructure, yet even in this context, the 
increasing move to HPV primary screening will bring about sizeable reductions in the overall cytology 
workload. Adequate recruitment, training and retention of cytology staff in an era of HPV primary 
screening may prove challenging and efforts to address this are required.  A novel approach to 
automated cytology that achieves performance similar to expert manual evaluation may serve as 
mitigation to these challenges (16). 
 
 
 
HPV Genotyping 
Current HPV tests include 13-14 HPV genotypes that vary substantially in their association with cervical 
cancer and pre-cancer (Table 2). The variation in risk has prompted development of genotyping 
strategies for triage purposes. In cervical cancer, by far the most important type is HPV16, followed 
by HPV18. However, there is some regional variation of type prevalence that could affect which types 
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are included in screening and triage assays (17). While HPV16 is also dominant in CIN3, HPV31, 33, 52, 
and 58 are more common than HPV18 (Table 2). There are several important considerations that affect 
HPV genotyping-based triage: 1. Detection of a specific HPV genotype cannot differentiate between a 
transient infection and a prevalent precancer. 2. HPV genotype detection predicts risk of precancer 
over many years. Thus, women may be at increased risk of future precancer, but they may not have 
any detectable lesions. 3. Deciding which types to include in a triage genotyping assay must balance 
the prevalence of the type in disease and in the healthy population, measured by the absolute risk of 
disease related to genotype. These points demonstrate that unavoidably, there is some unnecessary 
colposcopy referral with genotyping. Table 3 shows the absolute risk of CIN3+ and CIN2+ for genotypes 
in a large population of HPV-positive women. Importantly, the ranking of types may differ depending 
on chosen endpoint; CIN3+ is generally preferable since many CIN2s regress spontaneously (18). 
Several commercial HPV assays, some of which have been FDA-approved and or clinically validated via 
other means offer partial genotyping, typically measuring at least HPV16 and HPV18 (19). Current US 
guidelines recommend immediate referral of HPV16/18 positive women with normal cytology to 
colposcopy in a HPV-cytology co-testing strategy (20). A recently FDA-approved strategy, endorsed by 
interim expert consensus, recommends immediate referral of HPV16/18-positive women, with 
cytology triage of women positive for other HR types (2). Furthermore, recent data from the US show 
that extended genotyping (up to nine types or combinations) combined with cytology can provide 
refined risk-stratification through the identification of type-specific persistence (21). 
 
p16 +/- Ki67 
p16INK4a (or p16) is a cellular protein which highlights disruption of the retinoblastoma (RB)/E2F 
pathway related to activity of the HPV oncogene E7. The diagnostic application is through 
inmmunocytochemistry (or histochemistry), initially as a single marker and now as a dual stain with 
Ki67 (a proliferation marker which confers additional specificity) [22-25]. While p16 staining still 
requires a level of morphological interpretation, it can reduce pattern-complexity by allowing focus 
on a small subset of p16-stained cells. In contrast, for the dual stain, the criterion for positivity is a 
single cell with a simultaneous brown cytoplasm (p16) and a red nucleus (Ki67). The longitudinal 
accuracy of p16 immunostaining (without Ki67) as a triage of HPV positive women was studied within 
the NTCC trial (26). In women 35–60 years, the risk of CIN3+ at 3 years was 4.7% among HPV+/p16+ 
women compared to 0.8% in HPV+/p16- women. Furthermore, 83.7% of women who had a CIN3+ at 
follow-up were p16+ at baseline. The authors concluded that HPV+/p16+ positive women warrant 
immediate colposcopy whereas HPV+/p16- women could defer follow-up for at least 2 years.  More 
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recently, three studies have reported on dual-stained cytology as a triage of HPV-positive women, 
within primary screening cohorts (27-29); all of which have indicated that dual-staining may enhance 
the sensitivity of cytology. The largest (n=7727) was nested into the Athena trial (29) and showed that 
for CIN3+ detection, sensitivity of dual-stained cytology vs Pap cytology was significant higher (74.9% 
vs. 51.9%), as was NPV and PPV; whereas specificity was equivalent.  Immediate colposcopy referral 
of all HPV16/18+ women combined with dual-stained cytology of women positive for non-16/18 
genotypes provided the highest sensitivity for CIN3+ (86.8%). Additionally, a recent Scottish study 
showed higher sensitivity but lower specificity of dual stained, compared to conventionally stained, 
cytology (30).  It has been argued that the dual stain can reduce the requirement for “expert” cytology 
through simplifying interpretation and may improve inter-operator variability compared to traditional 
cytology (31). However, a recent study showed important differences in inter-observer reproducibility 
according to a laboratory’s experience highlighting the need for robust training and quality assurance 
(32). In summary p16/ki67 dual stain is a credible tool for risk stratification of HPV-positive women 
and compares favourably to cytology (33). Head to head comparisons now need to consider the cost 
effectiveness of this strategy compared with other stand-alone and combination options. 
 
Cellular and Viral Methylation Assays for Triage of HPV Infection 
Methylation has a fundamental role in the development and outcome of malignancies and can be 
measured accurately and easily by automated methods. Approximately ten human genes have 
consistently elevated methylation in cervical precancers and hypermethylation in most cancers, hence 
the appetite to focus on methylation targets for triage purposes (34,35). Of prominence are CADM1, 
EPB41L3, FAM19A4, MAL, miR-124, PAX1 and SOX1. Methylation of certain HPV genes including L1 
are also associated with precancer and invasive disease, especially for types HPV16, HPV18, HPV31, 
HPV33 and HPV45 (36,37). Table 4 shows the performance of human and HPV gene classifiers as triage 
tests for cervical precancers (38). MAL and CADM1 have been investigated extensively in hrHPV+ 
women; in one study of a screening population with a precancer and cancer endpoint (collectively 
CIN2+) these genes gave a sensitivity of 84% (95%CI 72-93), specificity of 52% (48-57), and AUC of  0.72  
(39). In the same set of women the sensitivity and specificity of cytology were 66% (50-79%) and 79% 
(74-83%) respectively (40). More-recent studies on screening and colposcopy populations using a 
variety of human gene targets showed sensitivity ranging from 69 to 74% with specificity (for CIN2+) 
ranging from 66% to 76% (38).  A more comprehensive approach is to test for methylation of HPV and 
human genes. For example, a combination of DAPK1 and HPV on samples from a US colposcopy 
population gave a sensitivity of 80% and a specificity of 89% for CIN2+. Another study on a combination 
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of EPB41L3 and HPV in a UK colposcopy population gave a sensitivity of 90%, specificity of 49%, 
AUC=0.82 (38). Given that performance in a colposcopy population does not necessarily translate to 
performance in a screening population the EPB41L3-HPV gene combination was validated in a 
separate study of hrHPV positive women from a screening population in the UK and gave a sensitivity 
of 74% (59-85%), specificity of 65% (60-70%), and AUC=0.78 (Table 4) (41). In comparison HPV16 and 
HPV18 genotyping on the same samples had a significantly poorer performance as a triage (P<0.0001). 
Methylation testing is still in the early stages but is showing good promise as an accurate molecular 
classifier. Technical improvements will likely improve clinical performance and can be expected in the 
next 5 years. Furthermore, even if methylation testing can deliver equivalent (rather than improved) 
performance compared to robust cytology, there are still positive aspects to this method including 
objectivity, consistency and applicability to automation and self-taken samples. 
 
Special considerations – triage of self-collected specimens 
Offering self-sampling of cervico-vaginal material for HPV testing (HPV self-sampling) is an effective 
tool to increase screening coverage (42). Moreover HPV testing on self-samples is as accurate as on 
clinician-taken samples if target-amplification assays are used (43). However, as cytology is not reliably 
applicable to self-taken samples, (43,44) offering cytology as a triage of women positive on their self-
sample would  necessitate a clinic visit. This confers a significant risk of loss to follow-up yet the issue 
would be circumvented if the triage test could be applied directly to the residual self-sample. In 
contrast to microscopy-based assays, molecular tests do not require the preservation of intact cells 
and may be used directly. The detection of (hyper) methylation of host cell genes by quantitative 
methylation-specific PCR (qMSP) on both self-collected vaginal lavages and brushes is feasible and 
shows promise as a triage (45-49).  
A recent RCT where qMSP for host genes MAL and miR124-2 was compared to cytology (on an 
additional smear) as a triage of HPV positive self-samples, demonstrated that the qMSP was non 
inferior to cytology for the detection of CIN2+ (50).  While the clinical performance of the qMSP did 
not exceed that of cytology, the logistic advantages/efficiencies of being able to apply the screening 
and triage assay to the same sample are clear.  There is also evidence to suggest that certain 
methylation markers have the advantage of giving a very high reassurance for absence of cervical 
cancer or advanced CIN2/3 lesions with a high short-term progression risk in test negative women 
(50,51).  Finally, as with the other markers considered in this roadmap, it is perhaps prudent not to 
consider methylation biomarkers as only applicable in isolation. A study in which the performance of 
the FAM19A4 and miR124-2 methylation biomarker was assessed (51) showed that the addition of 
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HPV16/18 genotyping results increased the sensitivity for CIN2+ significantly. The combination 
approach of 16/18 genotyping with methylation has parallels with combining cytology with HPV16/18 
genotyping, with the former offering a pathway to full molecular screening and triage. 
 
The role of next generation sequencing and viral genomics 
Advances in next-generation sequencing (NGS) technologies have enabled the sequencing of HPV 
whole-genomes in a high-throughput, cost-efficient manner. The large-scale study of HPV genome 
variability will advance a deeper understanding of HPV biology and mechanisms of HPV 
carcinogenicity, which may help to improve the design of triage tools in the future. NGS has already 
generated important information about carcinogenesis and natural history of HPV (52-54). For 
example, it has demonstrated that HPV 16 sub-lineages confer differential risks for disease as well as 
different tropisms for morphological lesion-type [53, 55-70].  Among 3,215 HPV16-positive women in 
the U.S., the HPV16 A4, D2, and D3 sub-lineages conferred significantly increased risks for glandular 
lesions compared to the more common A1/A2 sub-lineages (53). An international study of invasive 
cancers also found an enrichment of specific lineages in adenocarcinomas (67).  A triage test 
incorporating detection of a variants specific for adenocarcinoma could be used to enhance the 
detection of glandular lesions. At the level below a sub-lineage there is an HPV isolate which is a 
genome differing by ≥2 nucleotides from all others.  NGS has shown that thousands of unique HPV16 
isolates exist (54).  
Further, transient HPV16 infections have been shown to have a higher number of single nucleotide 
polymorphisms compared to transforming infections (54). Notably, the strict genetic conservation of 
E7 was associated with a greater risk of HPV16 driven carcinogenesis (54). The level of genetic 
variation in specific regions of the viral genome is important and could inform the design of future 
triage tools.  Finally, given that NGS is capable of rapid sequencing of both host and viral genes the 
technology lends itself to identifying several potential biomarkers of significance to infection and 
precancer concurrently such as HPV genotyping detection, variant classification and detection of 
somatic mutations. 
 
Low and middle income countries (LMIC) 
Cervical screening in LMIC is clearly associated with very different challenges from screening in high 
income countries (HIC). WHO Guidelines recommend visual inspection with acetic acid (VIA) for 
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population based screening or HPV testing if it can be afforded (3). However, most current HPV tests 
are designed for HIC and a new generation of tests which address the challenges in LMIC are needed 
(Text-box 1).  Unless these issues are addressed, both primary HPV testing and associated triage could 
remain largely HIC issues.  Options for triage in LMIC are associated with particular challenges. The 
lack of cytologists, pathologists and associated quality assurance usually means cytology-based 
protocols cannot be contemplated. Effective triage in a single “screen and treat” visit would overcome 
the challenges of follow-up and restricted opportunities for intervention in LMIC, but requires  a 
simple, quick, affordable and objective biomarker test performed on the same sample as the primary 
screen.  
Neither limited genotyping nor current biomarkers would satisfy these conditions. Work in rural 
Malawi has shown that trained staff who maintain a regular workload and adequate continued 
professional development can use VIA directly to differentiate treatable lesions and suspicious / 
advanced cancers (71,72)  but that prior knowledge of HPV results can aid judgment and inform clinical 
management (73).  Sending all HPV positive women for immediate treatment will result in over 
treatment, whereas restricting VIA to HPV positives may well entail a significant loss in sensitivity yet 
could address problems of capacity and retention of competent VIA providers. Inevitably, the trade-
off between resources available and programme outcomes needs to be assessed country by country 
and this is an area of great interest as outlined in recent reviews (74,75).  Many LMIC have not 
implemented HPV primary screening due to the cost and challenges identified, whereas roll-out of a 
VIA service, while potentially more practicable is challenged by the need for ongoing quality assurance 
and monitoring.  Use of less than 3 doses of HPV vaccine together with GAVI pricing have greatly 
advanced the potential for LMIC to consider national programmes (76). A combination of  vaccination 
of adolescent  girls and VIA for adult women may provide a better approach than HPV primary 
screening and an appropriate, as yet unidentified triage test although more evidence is needed to 
support this.  To this end, projects built around the HPV FASTER recommendation [(of extending 
routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups 
in certain settings)], paired with at least one HPV-screening test at age 30 years  will  provide important 
data (77).  
 
Triage for immunised women 
The impact that HPV immunisation programmes have conferred on both infection and disease is now 
clear at the population level in several countries. (78)  The evidence of herd immunity and the 
potential utility of even one dose of vaccine adds to these encouraging observations, for the countries 
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that can afford immunisation programmes (79,80). However, immunisation does present certain 
challenges for screening. The predictive value of any screening test will be influenced by the level of 
disease in the population (81). Furthermore, the fraction of HR-HPV infections in vaccinated 
populations attributable to 16/18 will be significantly lower; in a recent study of females immunised 
aged 12-13, over 90% of residual HR-HPV infections at age of first screen were not HPV 16 or 18 (82). 
As a wealth of evidence demonstrates that non 16/18 HR-HPV types confer a lower risk for CIN2+, the 
PPV of HR-HPV screening may reduce so appropriate triages are even more relevant in vaccinated 
populations (1).  Limited genotyping in this population is likely to have diminishing returns given the 
scarcity of 16/18 positive infections and it is arguable that non-viral targets may be more appropriate 
or assays that offer genotyping beyond HPV 16/18.  There have been few assessments of cytology 
triage specifically in immunised women (with or without adjunctive staining). Evidence of 
deterioration in the predictive value of cytology as a primary screen in immunised women has been 
documented, although this does not translate into poor performance as a triage of HR-HPV positive 
samples (83).  It is also worth noting that the extent of triage in immunised populations will reduce 
given evidence from modelling studies that indicate 10-year screening starting aged 30 is optimal 
(84,85). Conclusions from modelling endeavours, while extremely helpful, clearly incorporate various 
assumptions and differing levels of vaccine-uptake, type of vaccine and dimensions of programme 
(including the detail of catch up immunisation) will exert influence. This makes a comprehensive, “one 
size fits all” solution difficult (1). In line with this, one of the recommendations from a recent Italian 
conference on screening for vaccinated women was that modifications to the status quo should only 
be imposed on women vaccinated routinely rather than as part of a catch up programme (86). 
Furthermore, offering optimal screening and triage to increasingly mixed populations of immunised 
and unimmunised women, without creating impractical algorithms, and conflicting public-facing 
message(s) is a key challenge facing the community. 
 
Appropriate educational initiatives 
The transition from cytology to HPV-based screening presents unique challenges for patients and 
providers. With HPV screening, receipt of positive findings may result in a shift in the clinical discussion 
from an oncologic to a communicable disease approach. Despite the fact that HPV is the most 
prevalent STI worldwide (87), there is a lack of awareness about HPV among the general population 
(88,89). Women may feel anxiety, or shame when informed they are HPV positive (90). Clinicians often 
feel ill-equipped to manage the questions of HPV positive women (91). These concerns could 
ultimately affect acceptance of a superior screening technology if implementation is not carefully 
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planned, irrespective of what the subsequent triage may be.  Key messaging should be developed to 
address the concerns around an HPV positive result: De-stigmatize HPV by emphasizing the high 
prevalence; Highlight HPV positivity does not indicate a woman has or will develop cervical cancer; 
Ensure women are aware HPV may have been present for years, and does not reflect partner infidelity 
or promiscuity; Move the focus of HPV testing from “STI identification” to an enhanced test for cervical 
cancer prevention.  A key indicator of a woman’s intention to receive HPV testing is endorsement by 
her care provider (92); therefore, clinicians play a significant role alleviating distress by being prepared 
for the concerns and questions women will have. Cytology has been the primary cervical screening 
tool for decades. As a result, programs must invest appropriate time and resources to plan for HPV-
based testing irrespective of the triage used. Without such investment, lack of engagement from both 
patients and providers could jeopardize successful acceptance, resulting in decreased attendance for 
screening or increased health system costs due to non-compliance with extended screening interval 
guidelines.  
 
Conclusions 
The choice of appropriate triage strategy for HPV positive women is one of the key issues facing the 
cervical-screening community at present. As outlined above, there are various options associated with 
varying levels of evidence that either exploit considerable, existing expertise in morphological 
assessment or take advantage of recent developments in molecular technologies.  Currently, there is 
no single approach which offers a binary solution of referral to colposcopy for the positives and routine 
recall for the negatives, with the HPV positive-triage negative group (whether by cytology, typing, or 
methylation markers) representing a challenge.  Technical refinement of molecular approaches and/or 
the appropriate combination of more than one option, either concurrently or in a step-wise fashion 
may deliver benefits provided the complexity and cost are not prohibitive. Defining an acceptable level 
of risk is also important to help calibrate triage tools to appropriate performance standards at the 
population level. For European settings, it has been proposed that triage positive women should have 
(minimum) 20% risk of CIN2+ to indicate colposcopy, whereas triage negative women should have a 
risk of <2% of CIN2+ to indicate routine recall (93).  These settings are lower in the US (94).  
Longitudinal data from national HPV primary screening programmes, where alternative triage options 
have been used will continue to be important and should ideally be stratified by vaccination status. 
Finally, should there be a move to an entirely molecular option for cervical screening, possibly in 
combination with self-sampling, communications around this paradigm shift must be managed 
carefully to ensure informed informed engagement and sustainable uptake. 
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Country  Screenin
g policy† 
1st triage  2nd triage Reference 
Australia/ 
New Zea- 
land 
HPV 
alone 
HPV16/18+: 
colposcopy 
hrHPV other: LBC: 
• if HSIL+: 
colposcopy 
• if <=LSIL: 2nd 
triage 
At 12 M: hrHPV testing:  
• If +: colposcopy,  
• If –: routine screening  
http://wiki.cancer.org.au/australiawiki/images/a/ad/ 
National_Cervical_Screening_Program_guidelines_long-
form_PDF.pdf 
England 
(pilot study) 
* 
HPV 
alone 
Current pilot (6 sites) 
algorithm: cytology, 
if ASC-US+: 
colposcopy, if NILM: 
2nd triage.   
 
HPV16/18 typing  
also assessed in 
component of pilot 
sites where 
persistent 16/18 
positivity at 1st and 
2nd triage = 
colposcopy 
For pilot studies: 
At 12 M: hrHPV testing: 
• If +: colposcopy,  
• If –: routine screening 
TBD for roll out 
https://www.gov.uk/government/publications/human-
papillomavirus-hpv-primary-screening-protocol 
Germany 
** 
cotesting If ASC-H, AIS, HSIL: 
colposcopy, if NILM-
LSIL: 2nd triage. 
At 6-12 M: cotesting 
• If + (any test): colposcopy 
• If –: routine screening 
P. Hillemans, Department of Gynaecology and Obstetrics, 
Hannover Medical School; https://www.g-
ba.de/institution/presse/pressemitteilungen/641/ 
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Ireland 
*** 
HPV 
alone 
Cytology, if ASC-US+: 
colposcopy, if  NILM: 
2nd triage. Inclusion 
of limited typing 
likely but not yet 
defined. 
To be determined. 
Health Technology Assessment (HTA) of human 
papillomavirus testing as the primary screening method for 
prevention of cervical cancer. Health Information and 
Quality Authority. May 2017 
https://www.hiqa.ie/sites/default/files/2017-
05/HPV%20HTA%20technical%20report-
%2026052017_updated.pdf 
Italy 
**** 
HPV 
alone 
Reflex cytology, if 
ASC-US+: colposcopy, 
if NILM: 2nd triage. 
At 12 M: hrHPV testing: 
• If +: colposcopy,  
• If –: routine screening 
http://www.gisci.it/documenti/convegni/firenze2014/work
shop/carozzi_gisci_20140611.pdf 
 
Netherlands HPV 
alone 
Cytology, if ASC-US+: 
colposcopy, if  NILM: 
2nd triage.  
At 6M: cytology 
• If ASC-US_. Referral to colposcopy 
• If  NILM: routine screening 
http://www.britishcytology.org.uk/resources/Primary_HPV
_screening_The_Dutch_experience.pdf 
 
Norway 
***** 
HPV 
alone 
Reflex cytology if 
ASC-US+: colposcopy. 
If reflex 
cytology=NILM 2nd 
triage. 
At 12 M: hrHPV testing 
• If +: colposcopy,  
• If –: routine screening 
Ameli Trope & Mari Nygard, Norwegian Cancer Registry 
Scotland HPV 
alone 
Cytology, if ASC-US+: 
colposcopy., if NILM: 
2nd triage. 
At 12 M: hrHPV testing: 
• If +: colposcopy,  
• If –: routine screening 
Tracey Curtis, National Services Division and Timothy 
Palmer, Univeristy of Edinburgh 
Sweden 
****** 
HPV 
alone 
Cytology, if ASC-US+: 
colposcopy 
At 36M: cytology 
• If ASC-US_. Referral to colposcopy 
If  NILM: routine screening 
http://www.socialstyrelsen.se/riktlinjer/nationellascreening
program/livmoderhalscancer-screeningme 
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Turkey HPV 
alone 
HPV genotyping and 
evaluation of CP 
which is taken at 
same time as 
specimen for HPV 
screening (only used 
when hrHPV+). 
If cytology=ASC-US+: 
or if HPV16/18 
regardless of 
cytology results: 
colposcopy. 
If HPV positive for 
other than HPV16/18 
and smear is NILM: 
2nd triage. 
At 3-6M: hrHPV testing. If hrHPV-: routine screening. if 
hrHPV+: genotyping and evaluation of CP with same 
algorithm as 1ary triage.  If cyto=NILM and other 
hrHPV: 3rd triage 3-6M later. 
 
Turkey: M. Gultekin, Cancer Control Department, Public 
Health Institute, Ministry of Health, Ankara. 
http://kanser.gov.tr/Dosya/Kitaplar/turkce/Turkiye_Kanser
_Kontrol_Program_ing.pdf 
USA  Cotest Immediate referral of 
HPV-positive ASC-US, 
any LSIL+ 
HPV+/NILM 2nd 
triage. 
Repeat HPV/cytology. If either HPV+ or ASC-US+, 
referral to colposcopy 
If co-test negative, routine screening. 
Saslow et al (2012), Ref. 20 
 
HPV 
alone 
HPV16/18+: 
colposcopy 
hrHPV other: reflex 
LBC, if >=ASC-US: 
colposcopy; if reflex 
LBC=NILM: 2nd triage. 
at 12M: repeat cotest. If either HPV+ or ASC-US+, 
referral to colposcopy 
If co-test negative, routine screening. 
Huh et al (2015), Ref. 2 
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Table 1: Active or proposed triage policies for HPV-based screening 
ASCUS: Atypical Squamous Cells of Undetermined Significance 
CP: conventional Pap smear 
LSIL: Low grade squamous intraepithelial lesion 
NILM: Negative for intraepithelial lesion or malignancy 
 
† For a description of the details of the screening policies see Wentzensen et al (1) 
*Final decision on 1st & 2nd triage options for national roll out in England to be determined. 
** Triage policy still needs national approval in Germany.  
*** 2nd triage test is not yet determined for Ireland. 
**** - Cytology for women 25-33 years. HPV alone for women 34-64 years  
***** - Cytology for women 25-33 years.  HPV alone for women 34-69 years.  
******Cytology is offered to women 23-29 with HPV only interval=3y, age 30–49, with one cotest at age 41; HPV only, interval=7y, age 50–64. Non-
participating continue to be invited yearly up to age of 70. 
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HPV 
type 
Invasive cancer 
(n=40,679) 
CIN3  
(n=11,618) 
HPV16 64.7 54.5 
HPV18 16.5 4.9 
HPV58 5.5 10.8 
HPV33 5.1 11.0 
HPV45 4.3 1.7 
HPV52 3.7 10.9 
HPV31 3.5 10.7 
HPV39 1.5 1.5 
HPV59 1.3 0.8 
HPV35 1.2 3.1 
HPV56 0.9 1.5 
HPV51 0.8 3.5 
HPV68 0.6 1.1 
Multiple 11.9 15.8 
Table 2: Prevalence of carcinogenic HPV types as a proportion of HPV-positive samples in 
cervical cancers and CIN3 worldwide [genotype-specific positivity includes that contributed 
by multiple HPV infections. [Adapted from Guan IJC 2012 (16)]. 
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Type or type 
combination 
CIN3+ 
absolute risk 
CIN2+ 
absolute risk 
16 22.5 35.6 
18 11.7 20.7 
31 8.5 20.7 
33/58 8.5 18.8 
45 6.1 11.1 
52 5.8 16.2 
51 2.7 8.9 
39/68/35 2.1 8.1 
59/56/66 1.5 5.6 
Table 3: Absolute risk of CIN3+ and CIN2+ for genotypes and genotype combinations in HPV-
positive women from Kaiser Permanente Northern California. 
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Genes Sensitivity % Specificity % PPV % 
C13ORF18JAM3 
ANKRD18CP 
74 76 NA 
FAM19A4 70 
 
66 
 
55 
EPB41L3 
HPV16/18/31/33 
74 
 
65 
 
28 
 
EPB41L3 
HPV16/18/31/33 
90 49 51 
CADM1 
MAL 
miR-124 
89 50 52 
PAX1 44 95 83 
PCDHA4 
PCDHA13 
75 80 73 
DLX1 
ITGA4 
RXFP3 
SOX17 
ZNF671 
77 86 NA 
CADM1 
MAL 
62 
 
78 
 
49 
 
JAM3 
EPB41L3 
TERT 
55 
60 
62 
90 
57 
62 
NA 
NA 
NA 
FAM19A4 69 70 42 
MAL 
Mir-124 
72 
 
49 
 
29 
 
CADM1 
MAL 
miR-124 
48 81 NA 
JAM3 
TERT 
EPB41L3 
C13ORF18 
65 
 
77 NA 
CADM1 
MAL 
84 52 25 
 
Table 4. Performance characteristics of selected DNA methylation studies in exfoliated cervical cells 
for CIN2+.The combination tests typically used any gene marker as positive, but see reference 37 for 
specific details.  
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• Small collection volumes are cheaper and make storage, transport, and disposal of plastics 
and fluids easier; systems designed a priori for cytology are wasteful 
• Readily available simple blood collection tubes could be used for sample collection 
• Self-collected vaginal specimens  are more acceptable than clinician-collected specimens to 
women and especially  in cultures where gynaecological examination requires a husband’s 
permission 
• Tampon-like collection devices are easy to use, favoured by women in certain settings and 
may be able to be transported without fluid  
• HPV tests should be cheap, simple to do, and reproducible by all levels of healthcare 
providers with short turnaround time (< 2 hours).  
• Point of care testing by clinic staff would enable ‘screen and treat’ programmes where 
women could complete the screening process in a single visit  
• Text Box 1 - Elements to consider in the development  of new generation of HPV tests 
appropriate for use in LMIC 
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